A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
收藏DataCite Commons2026-04-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007373/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine whether the addition of oral ixazomib to the
background therapy of lenalidomide and dexamethasone improves progression free survival (PFS)
in participants with relapsed and/or refractory multiple myeloma (RRMM).
提供机构：
Vivli
创建时间：
2021-08-25
